RWML
BMRN icon

RAFFA WEALTH MANAGEMENT, LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

RAFFA WEALTH MANAGEMENT, LLC’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$515 Sell
9
-1
-10% -$55 ﹤0.01% 1177
2026
Q1 		$565 Buy
10
+2
+25% +$117 ﹤0.01% 1051
2025
Q4 		$475 Hold
8
– – ﹤0.01% 1077
2025
Q3 		$433 Hold
8
– – ﹤0.01% 1093
2025
Q2 		$440 Hold
8
– – ﹤0.01% 1024
2025
Q1 		$566 Hold
8
– – ﹤0.01% 938
2024
Q4 		$526 Hold
8
– – ﹤0.01% 995
2024
Q3 		$562 Hold
8
– – ﹤0.01% 970
2024
Q2 		$659 Hold
8
– – ﹤0.01% 1002
2024
Q1 		$699 Sell
8
-28
-78% -$2.51K ﹤0.01% 984
2023
Q4 		$3.47K Hold
36
– – ﹤0.01% 468
2023
Q3 		$3.19K Hold
36
– – ﹤0.01% 462
2023
Q2 		$3.12K Hold
36
– – ﹤0.01% 483
2023
Q1 		$3.5K Hold
36
– – ﹤0.01% 465
2022
Q4 		$3.73K Sell
36
-12
-25% -$1.13K ﹤0.01% 438
2022
Q3 		$4.07K Hold
48
– – ﹤0.01% 428
2022
Q2 		$3.98K Hold
48
– – ﹤0.01% 443
2022
Q1 		$3.7K Buy
48
+12
+33% +$1K ﹤0.01% 475
2021
Q4 		$3.18K Hold
36
– – ﹤0.01% 536
2021
Q3 		$2.78K Hold
36
– – ﹤0.01% 520
2021
Q2 		$3K Hold
36
– – ﹤0.01% 505
2021
Q1 		$2.72K Buy
36
+8
+29% +$654 ﹤0.01% 553
2020
Q4 		$2.46K Hold
28
– – ﹤0.01% 508
2020
Q3 		$2.13K Hold
28
– – ﹤0.01% 479
2020
Q2 		$3.45K Hold
28
– – ﹤0.01% 376
2020
Q1 		$2.37K Hold
28
– – ﹤0.01% 397
2019
Q4 		$2.37K Hold
28
– – ﹤0.01% 363
2019
Q3 		$1.89K Buy
+28
New +$2.16K ﹤0.01% 406
2019
Q2 		– Sell
-28
Closed -$2.49K – 822
2019
Q1 		$2.49K Hold
28
– – ﹤0.01% 320
2018
Q4 		$2.38K Hold
28
– – ﹤0.01% 329
2018
Q3 		$2.71K Hold
28
– – ﹤0.01% 335
2018
Q2 		$2.64K Buy
28
+13
+87% +$1.14K ﹤0.01% 324
2018
Q1 		$1.22K Buy
+15
New +$1.29K ﹤0.01% 451
2017
Q1 		– Sell
-7
Closed -$580 – 441
2016
Q4 		$580 Hold
7
– – ﹤0.01% 685
2016
Q3 		$648 Hold
7
– – ﹤0.01% 603
2016
Q2 		$545 Hold
7
– – ﹤0.01% 641
2016
Q1 		$577 Hold
7
– – ﹤0.01% 634
2015
Q4 		$733 Hold
7
– – ﹤0.01% 498
2015
Q3 		$737 Hold
7
– – ﹤0.01% 487
2015
Q2 		$957 Hold
7
– – ﹤0.01% 406
2015
Q1 		$872 Hold
7
– – ﹤0.01% 426
2014
Q4 		$633 Hold
7
– – ﹤0.01% 556
2014
Q3 		$505 Buy
+7
New +$460 ﹤0.01% 626
2014
Q1 		– Sell
-7
Closed -$633 – 332
2013
Q4 		$633 Buy
+7
New +$475 ﹤0.01% 556

Other funds holding BMRN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
CF
Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

RAFFA WEALTH MANAGEMENT, LLC's BMRN Position: Q2 2026 in Review

RAFFA WEALTH MANAGEMENT, LLC reduced its BioMarin Pharmaceuticals (BMRN) stake by 10% in Q2 2026, selling an estimated $55 and leaving 9 shares worth $515. The position accounts for ﹤0.01% of the portfolio, ranked #1177.

RAFFA WEALTH MANAGEMENT, LLC first reported a position in BMRN in Q4 2013 and has held it in 44 quarters since. The position peaked at $4.07K in Q3 2022. 138 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • RAFFA WEALTH MANAGEMENT, LLC held 9 shares of BioMarin Pharmaceuticals worth $515 as of Q2 2026.
  • RAFFA WEALTH MANAGEMENT, LLC sold 1 BioMarin Pharmaceuticals share in Q2 2026, an estimated $55.
  • BioMarin Pharmaceuticals made up ﹤0.01% of RAFFA WEALTH MANAGEMENT, LLC's portfolio in Q2 2026, its #1177 holding.
  • RAFFA WEALTH MANAGEMENT, LLC first reported a position in BioMarin Pharmaceuticals in Q4 2013 and has held it in 44 quarters since.
  • RAFFA WEALTH MANAGEMENT, LLC's BioMarin Pharmaceuticals position peaked at $4.07K in Q3 2022.
  • 138 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on RAFFA WEALTH MANAGEMENT, LLC's 13F filing for Q2 2026, filed 27 Jul 2026.